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http://www.biomedcentral.com/1472-6769/12/4RESEARCH ARTICLE Open AccessIdentification Of Small Molecule TRABID
Deubiquitinase Inhibitors By Computation-Based
Virtual Screen
Tong Shi1†, Ju Bao2†, Nick X Wang2†, Jie Zheng2* and Dianqing Wu1*Abstract
Background: Wnt/β-catenin-mediated gene transcription plays important roles in a wide range of biological and
pathophysiological processes including tumorigenesis where β-catenin-mediated transcription activity frequently
elevates. TRABID, a deubiquitinase, was shown to have a positive Wnt/β-catenin-mediated gene transcription and
hence holds a promise as a putative anti-cancer target.
Results: In this study, we used a combination of structure based virtual screening and an in vitro deubiquitinase
(DUB) assay to identify several small molecules that inhibit TRABID DUB activity. However, these inhibitors failed to
show inhibitory effects on β-catenin-mediated gene transcription. In addition, expression of TRABID shRNAs,
wildtype TRABID, or the DUB activity-deficient mutant showed little effects on β-catenin-mediated gene
transcription.
Conclusions: TRABID may not be a critical component in canonical Wnt/β-catenin signal transduction or that a
minute amount of this protein is sufficient for its role in regulating Wnt activity.Background
The evolutionarily conserved Wnt signaling pathway
regulates various developmental processes during em-
bryogenesis and plays an important role for tissue
homeostasis in adults. Wnt signaling pathway also
plays an important role in tumorigenesis, particularly
the formation of inherited and sporadic colorectal can-
cer as result of adenomatous polyposis coli (APC) mu-
tation that leads to β-catenin accumulation in the
nucleus [1-4]. Nuclear beta-catenin binds to and func-
tions as a cofactor of lymphoid enhancer-binding factor
(LEF-1) [5] and T cell factors (TCF) [6] to stimulate the
transcription of Wnt target genes [7]. Wnt-β-catenin
signaling is essential in sustaining the cancer stem cell
phenotype and is also involved in the transformation
into malignant human squamous cell carcinomas [8].
The loss of Wnt signaling pathway component APC in* Correspondence: jie.zheng@stjude.org; Dan.wu@yale.edu
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reproduction in any medium, provided the orstem cells results in progressively growing neoplasia [9].
Activation of Wnt/TCF pathway is also a determinant of
lung adenocarcinoma metastasis to brain and bone. The
phenotype of those metastatic derivatives of adenocar-
cinoma resembles the bronchioalveolar stem cells [10].
Thus, it holds promises to prevent and/or treat cancers
by targeting Wnt signaling pathway components.
TRAF-binding domain (TRABID), one of deubiquiti-
nation enzymes, was recently reported to specifically
and positively regulate Wnt signaling pathway [11].
TRABID is composed of a TRAF-binding domain in the
C-terminus and three Zinc-finger (ZnF) motifs at the N-
terminus [12]. TRABID preferentially binds to lysine
63-linked polyubiquitin chains (K63 chains), but not
K48-linked polyubiquitin chains (K48 chains), and spe-
cifically cleaves K63 chains [11]. K63-linked ubiquitina-
tion was suggested to regulate substrate activity rather
than protein stability [13-16]. The catalytic residues of
TRABID reside in the OTU (ovarian tumor) domain
within the TRAF-binding domain [11].
The OTU domain is conserved within the members of
the OTU family of DUBs that include A20 and possess
the cysteine protease activity [17]. TRABID was also. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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biquitination. However, the direct interaction between
APC and TRABID was not detected [11]. Knockdown of
TRABID with RNAi resulted in downregulated expression
of canonical Wnt target genes and decreased Wnt tran-
scription activity, whereas its knockdown does not affect
TNF-2 pathway [11]. Epistasis analysis suggested that TRA-
BID might act downstream of beta-catenin stabilization
and affect the interaction of beta-catenin with LEF1 [11].
Furthermore, TRABID heterozygosity suppressed the rough
eye phenotype caused by ectopic Wingless expression in
fly, but did not affect the phenotypes caused by the inhib-
ition of Notch signaling or inhibition of EGF signaling.
These results suggest that TRABID might be a potential
drug target for controlling Wnt pathway activation [11].
In this study, we screened for small molecule inhibitors
of TRABID by employing a combination of structure
based virtual screening and an in vitro DUB assay. We
searched for compounds in a chemical library from the
National Cancer Institute that potentially bind to TRABID
catalytic site based on the crystal structure of A20 catalytic
domain [17]. We identified several compounds that are
able to inhibit the DUB activity of TRABID. However,
these inhibitors failed to show inhibitory effects on Wnt
activity. Furthermore, neither shRNAs that silenced TRA-
BID efficiently nor overexpression of wild type (WT)
TRABID or its DUB activity-deficient mutant showed in-
hibitory effects on canonical Wnt signaling activity.
Results and discussion
To screen for compounds that can inhibit TRABID DUB
activity in vitro, we established an assay to measure the
DUB activity of TRABID. Consistent with the previous re-
port by Tran et al. [11], we observed that recombinant
TRABID proteins purified from an E coli expression system
or pulled down from HEK293 cells overexpressing Flag-
TRABID by an Flag antibody were able to specifically
cleave hexa-K63 (Figure 1B,C), but not penta-K48 (data not
shown), ubiquitin chains. We also tested a TRABID DUB-
deficient mutant containing a substitution mutation
(C443A), a residue located in the OTU domain and critical
for its catalytic activity [11]. The mutation abrogated the
ability of TRABID to cleave the Hexa-K63 ubiquitin sub-
strate (Figure 1C), confirming the importance of this resi-
due for the DUB activity. Homology modeling of TRABID
OTU domain based on the crystal structure of A20 OTU
domain [17] revealed that the common cysteine catalytic
site was well conserved in TRABID. This site is character-
ized by a cysteine residue that forms an electrostatic net-
work with a histidine and a residue with an acidic side
chain. In TRABID, these 3 residues are C443, H596 and
D410, respectively, based on the homology model
(Figure 1D).Searching on the surface of the equilibrated structure of
TRABID OTU domain modeled from the crystal structure
of A20 OTU revealed that there was a potential pocket
adjacent to the catalytic center of OTU (Figure 1E). This
pocket is part of a distal ubiquitin binding site at the cata-
lytic site in A20 [17]. Because of its spatial proximity to
the catalytic site and its role in ubiquitin binding, it is rea-
sonable to postulate that targeting this site may block the
entrance of the substrates and hence inhibit the OTU
DUB activity. Of note, during the molecular dynamics re-
finement, considerable conformational changes occurred
in this site, making it more expanded comparing with the
pocket size in the A20 crystal structure (Figure 1F).
We performed hierarchical virtual screening towards this
pocket as described in the “Materials and Methods”, and
requested 200 compounds that were ranked highest in the
virtual screen and were provided with 125 by NCI. These
125 compounds were screened for their abilities to inhibit
the cleavage of Hexa-K63 ubiquitin by TRABID. Seventeen
of these compounds showed more than 50 percent (denote
with ++ in Additional file 1. Table S1) and five showed be-
tween 25–50 percent (denote with + in Additional file 1.
Table S1) inhibition of TRABID DUB activity. Figure 2A
shows a representative Western blot used in the TRABID
DUB activity assay. All of the positive compounds were
retested in a dose-dependent experiment. Figure 2B shows
the data for the two of the strongest inhibitors, which
showed the IC50 values of about 3 μM. Neither compound
showed significant inhibition of A20 up to 30 μM, though
both inhibited A20 at 100 μM (Figure 2C-D). Compound
NSC60650 as well as a number of other compounds shown
in Additional file 1. Table S1, which share similar chemical
structures to NSC112200 and NSC267309 (Figure 2E), did
not inhibit TRABID DUB activity (Figure 2B), suggesting
that the two hydroxyl groups and their locations on the
benzene ring may be important for the inhibitory activity.
The molecular modeling of the bindings of NSC112200,
NSC267309 and NSC60650 to TRABID OTU domain sug-
gests that while all three compounds can form electrostatic
interactions with the side chain of E522 and the backbone
NH of T556, both NSC112200 and NSC267309 can form
an additional hydrogen bond with the side chain of S491
(Figure 2F-H). Moreover, NSC112200 can form another
hydrogen bond with the side chain of S520, and its one of
methyl groups provides extra hydrophobic interaction with
the carbon atoms located at the side chain of R557
(Figure 2F). The rescoring of binding free energies by ICM
shows that the binding free energies of NSC112200 and
NSC267309 with TRABID OTU are quite similar
(−20.28 kcal/mol and −20.03 kcal/mol, respectively), while
the binding free energy of NSC60650 with TRABID OTU
is −16.89 kcal/mol, which is 3.39 kcal/mol higher than
NSC112200. On the other hand, the calculated binding free
energies of NSC112200 and NSC267309 with A20 OTU
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Figure 1 TRABID DUB activity assays and structural modeling of TRABID OTU domain. A) Sequence alignment of TRABID OTU domain and
A20 OTU domain, the identical (yellow) and homologous (green) pairs are highlighted. B,C) Cleavage of K63 Chains by Recombinant TRABID.
Hexa-K63 ubiquitin (0.01 ug/ul) were incubated with recombinant full length TRABID protein prepared from bacteria (B) or Flag-TRABID or
Flag-TRABID-C443S precipitated by anti-FLAG agarose from transfected HEK293T cells (C) for 3 hrs in the DUB reaction buffer. Samples were
analyzed by Western under a non-reducing condition using an anti-ubiquitin antibody. D-F) Modeled structure of TRABID OTU domain based on
the crystal structure of A20 OTU domain. The modeled catalytic site of TRABID OTU domain is shown in D. The detected potential pocket of
TRABID OTU domain is shown in E and the corresponding pocket in A20 is shown in F for comparison. The modeled Cys443 is highlighted in
sphere representation in E and F.
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the high binding free energy means a lower binding af-
finity, our modeling predictions are consistent with our
experimental data. TRABID was shown to play a posi-
tive role in canonical Wnt signaling, and its DUB activ-
ity appeared to be essential for this function [11]. We
hence tested the TRABID DUB inhibiting compounds
for their effects on canonical Wnt signaling. SW480 or
HCT116 colorectal cancer cell lines, which were used in
the previous study for TRABID’s role in Wnt signaling
[11], were transfected with a Wnt reporter gene con-
struct TOPFLASH and incubated with compounds for
24 hrs. Because these two cell lines contain mutations in
the APC and β-catenin genes, respectively, there was
high reporter gene activity in these cells (Figure 3A-B).
However, neither NSC112200 nor NSC267309 inhibited
the reporter gene activity (Figure 3A-B). As controls
knockdown β-catenin resulted in significant reduction
in Wnt reporter gene activity (Figure 3A,B). We also
tested other TRABID inhibitors in Additional file 1.
Table S1, and none of them inhibited the reporter gene
activity (data not shown). We then examined two en-
dogenous Wnt target gene expression. Neither Axin2
nor c-Myc expression in SW480 cells was affected by
NSC112200 or NSC267309 treatment (Figure 3C).
These results together suggest that TRABID might not
be involved in Wnt$β-catenin-mediated gene transcrip-
tion regulation. To further evaluate the role of TRABID
in the regulation of Wnt/β-catenin-mediated gene tran-
scription, we generated 6 constructs that produce six
independent shRNAs for TRABID. When these shRNAs
were coexpressed with TRABID cDNA in HEK293 cells,
they showed varying efficiencies in suppressing TRABID
expression with shTrbd5 and 1 being the most efficiency
and shTrbd2 and 4 showing little effects (Figure 4A).
We also evaluated their knockdown efficiencies using
quantitative RT-PCR analysis of RNAs from YFP-posi-
tive HCT116 transfectants (shRNA and YFP were in the
same transcript) (Figure 4B). However, expression of
these shRNAs had no inhibitory effect on Wnt reporter
gene expression in either SW480 or HCT-116 cells
(Figure 4C,D). These shRNAs also did not show inhibi-
tory effect on the expression of endogenous Wnt target
gene Axin2 in SW480 cells (Figure 4E). Furthermore,overexpression of wildtype TRABID or its DUB-deficient
mutant had little effects on Wnt reporter gene expression
in either SW480 or HCT-116 cells (Figure 4F,G) or in
HEK293 cells (Figure 4H). Thus, we failed to demonstrate
that TRABID has an important role in Wnt target gene
expression regulation in these two cancer cells.
Nevertheless, both TRABID inhibitors NSC112200 and
NSC267309, but not the non-active analog NSC60650,
inhibited the growth of not only the colorectal tumor cell
lines HCT-116 and SW480, but also two para-normal cell
lines NIH3T3 and HEK293 at 20 μM (Figure 5). These
compounds showed no effects on the growth of these cells
at 5 μM (data not shown). Because of the lack of effect of
Compound NSC60650 on cell growth, we believe that the
effects of Compounds NSC112200 and NSC267309 are
likely due to their inhibition of the deubiquitinase activity.
Wnt signaling plays a crucial role in cancer cell growth
and cancer stem cell maintenance, which are believe to
be responsible for cancer metastasis and poor prognosis
of chemotherapy. Thereby, regulation of Wnt signaling
holds promise in chemotherapy of cancer. TRABID, one
of K63-specific DUB enzymes, became an attractive can-
didate to achieve this task since it has been reported to
regulate Wnt signal positively [11], as inhibition of TRA-
BID presumably decreases Wnt signaling activity. How-
ever, in this study, we failed to confirm the notion that
TRABID positively regulates canonical Wnt signaling
based on several lines of evidence. Firstly, the com-
pounds, which blocked TRABID DUB activity in vitro,
failed to inhibit Wnt transcription activity in two tumor
cell lines whereβcatenin-mediated transcription are
known to be elevated. Secondly, the TRABID shRNAs
failed to downregulate Wnt/β-catenin-mediated tran-
scription activity or endogenous Wnt target gene Axin2
mRNA levels in these tumor cells. Thirdly, overexpres-
sion of WT and C443S mutant TRABID failed to show
any effect on Wnt target transcription activity. We did
observe that the siRNA described in the previous report
[11] was able to inhibit Wnt reporter gene activity
(Figure 4C-E). One possibility is that the effect of the
siRNA reported in [11] is off target. A less likely possi-
bility is that a minute amount of TRABID is sufficient
for its regulation of Wnt signaling in these cells, and our
shRNAs or inhibitors were not efficient enough to alter
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Figure 2 Identification of TRABID DUB inhibitors. A,B) Effects of compounds on TRABID DUB activity. Compounds (30 μM in A) were
incubated with Hexa-K63 ubiquitin and immunoprecipitated FLAG-TRABID for 3 hrs. Samples were then analyzed by Western under a non-
reducing condition using an antiubiquitin antibody. The DUB activity was quantified in B by determining the optical density of hexa-K48
ubiquitin bands at 50 kD. The band without TRABID was taken as 100% and the one with TRABID and DMSO as 0%. The experiments were
repeated three times in duplicates, and errors are less than 5%. C,D) Effects of compounds on A20 DUB activity. Hexa-K63 ubiquitin was
incubated with compounds and immunoprecipitated FLAG-A20 and analyzed by Western under a nonreducing condition using an anti-ubiquitin
antibody. Quantification of DUB activity in D was carried out as described in B. E) Chemical structures of NSC112200, NSC267309 and NSC60650.
F) Molecular modeling of the binding of NSC112200 to TRABID OTU G) Molecular modeling of the binding of NSC267309 to TRABID OTU H)
Molecular modeling of the binding of NSC60650 to TRABID OTU.
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http://www.biomedcentral.com/1472-6769/12/4Wnt activity. Nevertheless, the fly data [11] have already
suggested that TRABID might not be a core component
of Wnt signaling. The observation that the TRABID
inhibitors were able to inhibit cell growth suggests that
TRABID may have a role in cell growth regulation.
However, the mechanisms for this role of TRABID need
to be further investigated.
Conclusions
We have used computation-based virtual screen to identify
chemical inhibitors for TRABID, but failed to confirm that
TRABID has a significant role in Wnt signaling. Neverthe-
less, inhibition of TRABID may inhibit cell growth.
Methods
Construction of TRABID expression vectors and shRNA
expression vectors Vectors expressing GST-fused full length
(FL) and N-terminal fragment (NT) (amino acides: 1–354)
of human TRABID were constructed using pET-GST
vector (EMD Chemicals Inc., Gibbstown, NJ). Proteins
were expressed in bacteria and purified using glutathione
sepharose 4B (Roche Diagnostics, Indianapolis, IN). FLAG-
expression vectors for expression of the full-length and
DUB-deficient (C443S) TRABID in mammalian cells were
gifts from Dr. Hoanh Tran. FLAG-tagged proteins were
immunoprecipitated using the M2 agarose affinity gel
(Sigma-Aldrich, St. Louis, MO). TRABID DNA sequences
were confirmed by DNA sequencing. TRABID shRNA tar-
geting sequences were selected using the RNAi Codex algo-
rithm (http://katahdin.cshl.org:9331_portal_scripts_main2.
pl) [18] and the shRNAs were expressed using Migr-CMV-
YFP-miR30 vector as previously reported [19]. The shRNA
target sequences are: shTrabd1, TGTCTCAACAAGCAG
CAAAGT; shTrabd2, AGGAGCTAGGTAATGAGGAAC;
shTrabd3, TGTCAGAACGTGGAATTAAGT; shTrabd4,
TGATCATCCCAGACCTAATAA; shTrabd5, CTGGCAC
ATATTCTTAGACGA; shTrabd6, TTGGAAAAGTCCGA
TTGCTCT. β-catenin siRNA [20] and TRABID siRNA
[11] target sequence were described previously.
DUB enzymatic activity assay
For determining TRABID DUB enzymatic activity,
hexa-K63 ubiquitin (0.01 ug/ul, Boston Biochem Inc.,Cambridge, MA) and the compounds were incubated
with TRABID immunoprecipitated from transfected
HEK 293 T cells or prepared from bacteria for 3 hrs at
37°C in a DUB reaction buffer (50 mM HEPES at pH 7.4,
150 mM KCl, 10 mM DTT, 5% glycerol, 0.01% Triton X-
100) [11]. Samples were applied to SDS-PAGE under non-
reducing conditions and then transferred onto mem-
bers. Ubiquitin chains were detected using a rabbit anti-
ubiquitin antibody (Bethyl Laboratories Inc., Montgom-
ery, TX).For determining A20 DUB enzymatic activity,
Penta-K48 ubiquitin (0.04 ug/ul, Boston Biochem Inc.,
Cambridge, MA), 1.5 uM of A20 catalytic domain (Bos-
ton Biochem Inc., Cambridge, MA), and various con-
centrations of compounds were incubated for 3 hrs at
37 C in an A20 DUB reaction buffer (50 mM HEPES at
pH 8.0, 3 mM DTT, 0.01% Brij-35) [21].
Homology modeling and potential pocket identification
There are two crystal structures of A20 OTU domains
deposited in PDB with nearly identical sequences and struc-
tures. Because The OTU domain of A20, shared a high de-
gree of amino acid homology with that of TRABID, its
sturcutre is the ideal template for the homology modeling
of TRABID OTU structure. We used one of the A20 OTU
structures (from PDB ID 2VFJ [17]) as the template for
homology modeling.. The homology model of TRABID
was built by the Prime module of the Schrodinger molecu-
lar modeling package [22,23]. A 3 ns molecular dynamics
was performed by AMBER10 [24] to equilibrate the initial
model since there is considerable gap (15%) between the
sequences of TRABID and A20 (Figure 1A). The final equi-
librated structure is used for the further modeling. The
ICM PocketFinder module based on an algorithm of utiliz-
ing a Van de Waals grid potential map and a carbon probe
[25] was used to detect potential relevant pockets around
the catalytic cysteine residue of the TRABID OTU domain.Virtual screening
Since there is no any knowledge about the characteristics
and properties of the potential ligands, it is necessary to
search all the compounds in the library to find potential
hits. We thus carried out virtual screens of the National
Cancer Institute (NCI) database (http://129.43.27.140/
ncidb2) for chemical compounds that could potentially
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Figure 3 Effect of TRABID inhibitors on Wnt/β-catenin-mediated transcriptional activity. A,B) TRABID inhibitors fail to inhibit Wnt reporter
gene activity. HCT-116 or SW480 cells were transfected with FOPFLASH or TOPFLASH and a plasmid expressing Renilla luciferase and incubated
with the compounds for 24 hours. As a control the cells were also transfected with an β-catenin siRNA (siCTNNB). Normalized Wnt reporter gene
activity is shown. The experiments were repeated three times in triplicates C) Effect of TRABID inhibitors on endogenous Wnt target gene
expression in SW480 cells. SW480 cells were incubated with the compounds (20 μM) for 24 hours, and relative AXIN2 and c-Myc mRNA levels
were determined by qRT-PCR normalized on the levels of β-actin mRNA. Experiments are performed in triplicates, and data are presented as
means ± SD.
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determined by q-RT-PCR. C,D) Effects of TRABID shRNAs on Wnt reporter gene activity. HCT116 (B) or SW480 (C) cells were cotransfected with
FOPFLASH or TOPFLASH, Renilla luciferase, and one of the TRABID shRNAs. TOPFLASH activity was detected 72 hrs after transfection. E) Effects of
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extracted. The levels of Axin2 mRNA were determined by qRT-PCR using beta-actin as control. F,G) Effect of overexpression of TRABID WT or
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http://www.biomedcentral.com/1472-6769/12/4bind to the detected cavity. This database includes the
coordinates of 250,251 small (M.W. < 1,000 Da) chemical
compounds. In order to eliminate the large amount of ir-
relevant compounds we used Glide module [26,27] in the
Schrodinger package to perform hierarchical searches. The
scoring function of High-throughput in Glide, which is less
accurate but very fast, was used to perform the first roundscreening. Subsequently, the top 5000 compounds were
selected and further tested with the normal scoring func-
tion in Glide. Finally, the most precise, but slower, scoring
function in Glide [28] was used to perform the final screen-
ing with the top 500 compounds, and the top 200 com-
pounds were requested from NCI and evaluated by the
experimental assay.
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Figure 5 Effect of TRABID inhibitors on cell growth. Compounds (20 μM) were added to cells at seeding and cell growth was determined by
counting live cells at indicated times. Experiments are performed in triplicates, and data are presented as means ± SD.
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http://www.biomedcentral.com/1472-6769/12/4In order to further interpret the inhibitory mechanism,
the binding free energies of two strong TRABID deubiqui-
tinase inhibitors, NSC112200 and NSC267309, identified
in the screen were reevaluated by using the ICM empirical
function, which is fast and fairly accurate in predicting
relative binding free energies [29]. The binding free energy
of NSC60650, which shares similar chemical structure
with NSC112200 and NSC267309 but shows no inhib-
ition, was also recalculated for comparison. The overall
complexes were optimized and the binding free were cal-
culated using Equation:
ΔGbinding ¼ ΔGvw þ ΔGhb þ ΔGto þ ΔGel þ ΔGsf
Where ΔGvw is the Van der Waals energy, ΔGhb is the
htdrogen bonding energy, ΔGto is torsional energy, ΔGel
is electrostastic energy; and Δsf is the surface energy.
TOPFLASH reporter assays
For testing the effect of compounds, cells were seeded in
48-well culture plates at a density of 0.2-0.3 million/ml,
250 ul/well and transfected with TOPFLASH or FOP-
FLASH and Renilla luciferase using the Lipofectamine
Plus reagent (Invitrogen Corporation, Carlsbad, CA).The compounds were added 3 hrs later. For shRNA
knockdown experiments, cells were transfected with an
shRNA expressing plasmid and re-transfected with the
Wnt reporter gene plasmids and the shRNA two days
later. Wnt reporter gene activity was determined 24 hrs
after the re-transfection and presented after normalization
against the Renilla luciferase activity.
Quantitative RT-PCR
Cells were plated into 6 well plates at a density of
0.2 million/ml for 12–16 hrs. For compound inhibition
experiments, cells were incubated with 20 μM of a com-
pound for 24 hrs. For shRNA inhibition experiments, cells
were transfected with the shRNAs and incubated for
72 hrs. Total RNAs were extracted using the RNAeasy
mini kit (Qiagen, Valencia, CA) and transcripted into
cDNAs. The levels of Wnt target gene mRNAs were
determined using a MyiQ Single color real-time PCR de-
tection system (Bio-Rad, Hercules, CA) with beta-actin as
a control.
Cell growth assay
Cells were seeded at a density of 0.05 million/ml in 24-well
culture plates and added with 20 μM compound. On
Shi et al. BMC Chemical Biology 2012, 12:4 Page 10 of 10
http://www.biomedcentral.com/1472-6769/12/4indicated date, the numbers of living cells were counted
using Guava Easycyte Mini Flow Cytometry System (Milli-
pore Corporation, Billerica, MA).
Additional file
Additional file 1: Table S1. TRABID inhibitory activity and structures of
additional compounds.
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